




Engaging Patients in Injectable Therapy Selection for LDL-C Reduction in Secondary Prevention of ASCVD

Key Takeaways

-  Patient characteristics and lifestyle are important factors when choosing between siRNA and monoclonal antibodies for lipid-lowering intensification therapy
-  Ensure you have adequate information about your patient's public or private coverage before discussing specific therapies
-  Involve patients actively in the decision-making process to personalize their care and improve treatment outcomes

Choosing the right therapy is crucial for optimizing patient outcomes.

Engage your patients with ASCVD in the decision-making process to select a treatment option that best manages their dyslipidemia and improves:

- ✓ Adherence
- ✓ Self-satisfaction in their care
- ✓ Their health outcomes

There are **2 main injectable treatment regimens** for LDL-C reduction in secondary prevention or patients with FH: **siRNA therapy and monoclonal antibodies**. Both options demonstrate significant LDL-C reduction, and both have their own advantages, depending on individual patient needs and preferences.

	Inclisiran (siRNA)	Monoclonal antibodies
Dosing and administration	Administered by a healthcare professional every 6 months*	Self-administered Typically, once every 2 weeks or once a month
Logistical advantages	Certain patients may prefer infrequent administration: <ul style="list-style-type: none"> ✓ Needle phobia ✓ frail and require assistance with injections ✓ travel frequently ✓ busy schedules ✓ Snow birds 	Some patients find comfort in a regular treatment routine that aligns with their weekly or monthly schedules
Access	Patient support program for patients with private coverage	Public coverage depends on provincial reimbursement criteria Patient support program available for evolocumab

*Except for the first year of treatment, where the patient must receive 3 doses

Tips to effectively engage your patients in selecting an injectable therapy for LDL-C reduction in secondary prevention of ASCVD

- Be equipped with the following information before discussing treatment options with your patients:
 - ▶ The public reimbursement criteria in your province for the different treatments
 - ▶ Knowledge of whether your patient has private insurance
 - ▶ The different patient support programs available to facilitate access to specific drugs
- Understand your patient's comfort level with injections
- Evaluate with your patients what they value most in their treatment: routine, efficiency, etc.
- Discuss your patient's lifestyle and general schedule



www.aim-lo.com



Sign up now